Signals flagged in the original
Provisional estimate — refines shortly Full breakdown ↓
The FDA has required drug manufacturers to alert patients and healthcare providers about a potential risk of non-arteritic anterior ischemic optic neuropathy, or 'eye stroke,' associated with GLP-1 drugs used for weight management and diabetes treatment.
Our neutral summary
The FDA has required drug manufacturers to alert patients and healthcare providers about a potential risk of non-arteritic anterior ischemic optic neuropathy, or 'eye stroke,' associated with GLP-1 drugs used for weight management and diabetes treatment.
The reporting belongs to The Hill; we don't reproduce it.
No note attached
on this article.
FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs
FDA issues warning about potential eye condition linked to GLP-1 drugs